Inventor
HABER LAURIC
US20 patents
⚠️ This page may combine multiple inventors who share the name “HABER LAURIC”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
18 patentsUS10772972B2Sep 15, 2020
Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
REGENERON PHARMA44 citations97
US10738130B2Aug 11, 2020
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
REGENERON PHARMA50 citations97
US10179819B2Jan 15, 2019
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
REGENERON PHARMA25 citations93
US11155633B2Oct 26, 2021
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
REGENERON PHARMA9 citations85
US11548947B2Jan 10, 2023
Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof
REGENERON PHARMA10 citations84
US11453721B2Sep 27, 2022
Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
REGENERON PHARMA10 citations84
US11485793B2Nov 1, 2022
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA4 citations83
US10941208B2Mar 9, 2021
Anti-MUC16 antibodies
REGENERON PHARMA6 citations83
US12077603B2Sep 3, 2024
Multispecific antigen-binding molecules for cell targeting and uses thereof
REGENERON PHARMA3 citations72
US12065508B2Aug 20, 2024
Multispecific antigen-binding molecules for cell targeting and uses thereof
REGENERON PHARMA3 citations72
US11952430B2Apr 9, 2024
Multispecific antigen-binding molecules for cell targeting and uses thereof
REGENERON PHARMA3 citations72
US11633501B2Apr 25, 2023
Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
REGENERON PHARMA3 citations72
US12577304B2Mar 17, 2026
Anti-CD3 antibodies with low binding affinity
REGENERON PHARMA0 citations62
US12415856B2Sep 16, 2025
EGFR x CD28 multispecific antibodies
REGENERON PHARMA0 citations62
US12344677B2Jul 1, 2025
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
REGENERON PHARMA0 citations62
US11912767B2Feb 27, 2024
EGFR × CD28 multispecific antibodies
REGENERON PHARMA1 citations62
US12570764B2Mar 10, 2026
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA0 citations61
US12441800B2Oct 14, 2025
Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof
REGENERON PHARMA0 citations61